[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623755":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":38,"centralContacts":43,"locations":48,"responsibleParty":64,"collaborators":12,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":12,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":12,"enrollmentInfo":75,"targetDuration":12,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":51,"whyStopped":12,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",[8,13,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Care","NO_INTERVENTION","Participants receive standard care for active thyroid eye disease according to current clinical practice for 24 weeks.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Statin","EXPERIMENTAL","Participants receive standard care plus oral atorvastatin 20 mg once daily for 24 weeks.",[18],"Drug: Atorvastatin (Lipitor)",{"label":20,"type":15,"description":21,"interventionNames":22},"Vitamin D","Participants receive standard care plus oral vitamin D supplementation at a dose of 1400 IU daily for 24 weeks.",[23],"Dietary Supplement: Vitamin D",{"label":25,"type":15,"description":26,"interventionNames":27},"Statin plus Vitamin D","Participants receive standard care plus oral atorvastatin 20 mg once daily and oral vitamin D supplementation at a dose of 1400 IU daily for 24 weeks.",[18,23],[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":12},"DRUG","Atorvastatin (Lipitor)","Oral atorvastatin 20 mg administered once daily for 24 weeks.",[14,25],{"type":35,"name":20,"description":36,"armGroupLabels":37,"otherNames":12},"DIETARY_SUPPLEMENT","Oral vitamin D supplementation at a dose of 1400 IU administered once daily for 24 weeks.",[25,20],[39],{"name":40,"affiliation":41,"role":42},"Chin-Sung Kuo, MD, PhD","Taipei Veterans General Hospital, Taipei, Taiwan","PRINCIPAL_INVESTIGATOR",[44],{"name":40,"role":45,"phone":46,"phoneExt":12,"email":47},"CONTACT","886-2-28757513","cskuo@vghtpe.gov.tw",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":53,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Taipei Veterans General Hospital","RECRUITING","Taipei","Taiwan","11217","TW",{"type":57,"coordinates":58},"Point",[59,60],121.52639,25.05306,{"lat":60,"lon":59},[63],{"name":40,"role":45,"phone":46,"phoneExt":12,"email":47},{"type":65,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100623755","statin-and-vitamin-d-treatment-in-patients-with-thyroid-eye-disease-100623755",false,"NCT07400757","Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease","The Role of Statin and Vitamin D for the Treatment of Thyroid Eye Disease","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher\n* Low-density lipoprotein cholesterol (LDL-C) level of 100 mg\u002FdL or higher\n\nExclusion Criteria:\n\n* Prior orbital radiotherapy or orbital surgery for thyroid eye disease\n* Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment\n* Pregnancy\n* Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m²","ALL","20 Years",{"count":76,"type":77},120,"ESTIMATED","INTERVENTIONAL",[80],"NA","The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are:\n\n* Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis?\n* Does vitamin D supplementation change disease activity in patients with active thyroid eye disease?\n* Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care?\n* What adverse events occur during treatment?\n\nResearchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care.\n\nParticipants will:\n\n* Be randomly assigned to one of four treatment groups\n* Receive the assigned treatment for 24 weeks\n* Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks\n* Be followed through medical record review for up to three years after completion of the intervention",[83,84],"Thyroid Eye Disease, TED","Graves Ophthalmopathy",[86,84,14,20,87,88,89,90,91,92],"Thyroid Eye Disease","Atorvastatin","Autoimmune Disease","Inflammation","Randomized Controlled Trial","Factorial Design","Clinical Activity Score","2026-04-24",{"date":95,"type":96},"2026-04-30","ACTUAL",{"date":98,"type":96},"2026-02-24",{"date":100,"type":77},"2032-07-15",{"name":5,"class":6},1]